FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198729042> ?p ?o ?g. }

• W3198729042 endingPage "7156" @default.
• W3198729042 startingPage "7147" @default.
• W3198729042 abstract "Human heavy-chain ferritin (HFn) and hepatitis B virus core (HBc) are both nanoparticle proteins presenting a well-oriented architecture with constant size and shape, which can be engineered to carry epitopes on the surface of the nanoparticle protein cage, enabling vaccine design. This study aims to investigate the immunogenicity differences between engineered HFn and chimeric HBc bearing the same epitope. As a proof of concept, the model epitope Epstein-Barr nuclear antigen 1 (EBNA1) is inserted at the N-terminus of the HFn and HBc subunit to produce two vaccine candidates named EBNA1-HFn (E1F1) and EBNA1-HBc (E1H1), respectively. From in vivo immunogenicity studies, E1H1 demonstrates the capability to prompt significant humoral and cell-mediated immune responses in adjuvant-free formulation. When formulated with the aluminum hydroxide adjuvant, E1H1 produces approximately 5× higher titer and 2× stronger proliferation index (PI) than E1F1. These results confirm that the HBc carrier induces a stronger humoral immune response than HFn. On the other hand, from lymphocyte activation experiments, E1F1 induces a stronger cell-mediated immune response indicated by 5× more CD8+T cells and 2× more effector memory T cells in the E1F1 group versus the E1H1 group. Through this study, HFn and HBc are shown to be potentially effective vaccine carrier nanoparticles having subtly different immunological responses." @default.
• W3198729042 created "2021-09-13" @default.
• W3198729042 creator A5003395715 @default.
• W3198729042 creator A5048165624 @default.
• W3198729042 creator A5048667355 @default.
• W3198729042 creator A5049670106 @default.
• W3198729042 creator A5058771046 @default.
• W3198729042 creator A5063605100 @default.
• W3198729042 creator A5087252987 @default.
• W3198729042 date "2021-09-08" @default.
• W3198729042 modified "2023-10-16" @default.
• W3198729042 title "Immunogenicity and Vaccine Efficacy Boosted by Engineering Human Heavy Chain Ferritin and Chimeric Hepatitis B Virus Core Nanoparticles" @default.
• W3198729042 cites W1567772800 @default.
• W3198729042 cites W1583785918 @default.
• W3198729042 cites W1966012201 @default.
• W3198729042 cites W1972333400 @default.
• W3198729042 cites W1975197163 @default.
• W3198729042 cites W1990177413 @default.
• W3198729042 cites W1991089498 @default.
• W3198729042 cites W1991701295 @default.
• W3198729042 cites W1997322438 @default.
• W3198729042 cites W2001191983 @default.
• W3198729042 cites W2002844537 @default.
• W3198729042 cites W2005014362 @default.
• W3198729042 cites W2013887826 @default.
• W3198729042 cites W2015894758 @default.
• W3198729042 cites W2026608413 @default.
• W3198729042 cites W2031028589 @default.
• W3198729042 cites W2033420011 @default.
• W3198729042 cites W2035851795 @default.
• W3198729042 cites W2038092469 @default.
• W3198729042 cites W2039472971 @default.
• W3198729042 cites W2054648552 @default.
• W3198729042 cites W2056489903 @default.
• W3198729042 cites W2058720855 @default.
• W3198729042 cites W2072753827 @default.
• W3198729042 cites W2073151752 @default.
• W3198729042 cites W2078057851 @default.
• W3198729042 cites W2079876772 @default.
• W3198729042 cites W2083994938 @default.
• W3198729042 cites W2084782867 @default.
• W3198729042 cites W2094459870 @default.
• W3198729042 cites W2098123605 @default.
• W3198729042 cites W2107215997 @default.
• W3198729042 cites W2113847305 @default.
• W3198729042 cites W2128285319 @default.
• W3198729042 cites W2130503484 @default.
• W3198729042 cites W2136453261 @default.
• W3198729042 cites W2148059767 @default.
• W3198729042 cites W2148817537 @default.
• W3198729042 cites W2152467424 @default.
• W3198729042 cites W2152986015 @default.
• W3198729042 cites W2158790342 @default.
• W3198729042 cites W2164901745 @default.
• W3198729042 cites W2170904230 @default.
• W3198729042 cites W2170912872 @default.
• W3198729042 cites W2172319351 @default.
• W3198729042 cites W2195593931 @default.
• W3198729042 cites W2264544376 @default.
• W3198729042 cites W2531916724 @default.
• W3198729042 cites W2532652101 @default.
• W3198729042 cites W2560251643 @default.
• W3198729042 cites W2743927776 @default.
• W3198729042 cites W2753483322 @default.
• W3198729042 cites W2888204442 @default.
• W3198729042 cites W2893095288 @default.
• W3198729042 cites W2918359234 @default.
• W3198729042 cites W3015742158 @default.
• W3198729042 cites W3105210436 @default.
• W3198729042 cites W3141903784 @default.
• W3198729042 cites W3183250322 @default.
• W3198729042 cites W4234018633 @default.
• W3198729042 cites W4235436131 @default.
• W3198729042 cites W4253072178 @default.
• W3198729042 doi "https://doi.org/10.1021/acsabm.1c00738" @default.
• W3198729042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35006946" @default.
• W3198729042 hasPublicationYear "2021" @default.
• W3198729042 type Work @default.
• W3198729042 sameAs 3198729042 @default.
• W3198729042 citedByCount "5" @default.
• W3198729042 countsByYear W31987290422022 @default.
• W3198729042 countsByYear W31987290422023 @default.
• W3198729042 crossrefType "journal-article" @default.
• W3198729042 hasAuthorship W3198729042A5003395715 @default.
• W3198729042 hasAuthorship W3198729042A5048165624 @default.
• W3198729042 hasAuthorship W3198729042A5048667355 @default.
• W3198729042 hasAuthorship W3198729042A5049670106 @default.
• W3198729042 hasAuthorship W3198729042A5058771046 @default.
• W3198729042 hasAuthorship W3198729042A5063605100 @default.
• W3198729042 hasAuthorship W3198729042A5087252987 @default.
• W3198729042 hasConcept C104317684 @default.
• W3198729042 hasConcept C147483822 @default.
• W3198729042 hasConcept C159047783 @default.
• W3198729042 hasConcept C185592680 @default.
• W3198729042 hasConcept C195616568 @default.
• W3198729042 hasConcept C203014093 @default.
• W3198729042 hasConcept C2522874641 @default.
• W3198729042 hasConcept C2776387124 @default.

• next